Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
about
The Role of PARP Inhibitors in the Treatment of Gynecologic MalignanciesEpidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analysesEpidemiology and natural history of human papillomavirus infections in the female genital tractPapillomavirus genome structure, expression, and post-transcriptional regulationProphylactic human papillomavirus vaccinesIdentification of human papillomavirus type 16 L1 surface loops required for neutralization by human seraRandomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future.Virus-like particles production in green plantsHuman papillomavirus and HPV vaccines: a reviewEnhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cellsImmunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzeesPrevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, IndiaAdjuvants: Classification, Modus Operandi, and LicensingPreventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology GuidelineVaccine Adjuvants: from 1920 to 2015 and BeyondAre the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPVAn appraisal of theoretical approaches to examining behaviours in relation to Human Papillomavirus (HPV) vaccination of young womenMolecular cancer prevention: Current status and future directionsHuman papillomavirus vaccination: a case study in translational scienceCurrent status of human papillomavirus vaccinesViruses and human cancerAwareness and knowledge about human papillomavirus vaccination and its acceptance in China: a meta-analysis of 58 observational studiesNew Biomedical Technologies and Strategies for Prevention of HIV and Other Sexually Transmitted InfectionsHPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should knowLong-term efficacy and safety of human papillomavirus vaccinationConcatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccinesVLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirusEnhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE)Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine.Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programmeSustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.Determinants of seropositivity among HPV-16/18 DNA positive young women.Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong KongSafety of human papillomavirus vaccines: a review.Alternative technologies in cervical cancer screening: a randomised evaluation trial.A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consentProphylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.A vaccine against nicotine for smoking cessation: a randomized controlled trial
P2860
Q21129302-B7F13692-0B87-4292-AADC-2B9E29542002Q21144710-E228C3FC-56D9-46DB-8C22-6786CD38559BQ21284469-66DF4224-A498-4F0C-BA50-7FDC8F01B4E9Q22255483-A2E5CCCE-3C79-4F32-B66B-C8844769FC89Q24545449-8E4AC4B1-A7A2-4EAB-98DB-B0BFE8C198FDQ24545868-7E53F680-ECD3-4DD6-94C2-F0ADD92FE8A4Q24600011-6EF346DD-E07B-4FCE-8249-8176EA658EDCQ24650772-08D86CB8-C011-4379-AD29-0E1F81128722Q24657891-8D657D3D-4110-40BE-8E1E-42058F2C7D39Q24658494-FD4925CC-93AB-4413-A4F7-38E91B87F630Q24685256-B3D84710-C404-409B-8AD2-86A16C56194EQ25257293-20E6ACE4-7BA5-4979-97C0-33F509B9B438Q26747586-12514C5C-3225-4913-88C7-F393B44E4763Q26749285-B8A36B4A-A9FF-46D3-AC58-9E93C74EDB79Q26783879-29B1E165-2353-49B3-A45E-C55D12107D0FQ26783973-9798EC33-EF4E-4C91-8F19-6DBADBDE71E8Q26796532-55CD1963-8B9F-4EC9-87C3-F77C0D5B6FB4Q26797207-3F6F5AE7-F5FF-473E-8153-FC9AF119FCDFQ26853556-A11F29CD-1436-4FB8-8D2A-F4D92F2F550BQ26991640-3E61032B-F497-42A2-AD4B-D2CADE66D5C0Q27481175-8E285FD3-2AB4-404A-A7FA-1AAE6CFDEBF3Q28066373-AF5B23E0-932E-4A10-B99F-96ABE6989E49Q28072213-F9EAE6A1-59FE-4C8E-9441-590FE51998CFQ28072958-AE0A10BD-22E3-48EF-AC08-0010228F6E11Q28081156-CC8B91FE-87D8-493A-90A8-38CA15826917Q28246307-1BE9498E-D510-4E34-9C2F-5465886B6027Q28280059-9F083285-A73B-4D9E-B2C9-04F5C95F4C03Q28476101-31711090-5408-4735-A637-6E572D84AF81Q30354637-2E12DCA1-8DE5-4151-A3CF-53EFE495858CQ30384943-24C37710-87C5-40E2-90DD-BD478C4C5E10Q30573204-2B635D15-93D0-4E56-8E04-3C4AE0335F95Q30780649-FA5FC99E-A9D1-4CEB-92C4-E0606BB80A40Q30980654-976DF43C-CC9E-480A-9C6D-F136C2316589Q30986936-873E9635-290E-42A8-AEE9-8A2248B884B2Q31131825-5F8CD3E8-79D5-4348-80B1-2E8F25ACCED5Q33162724-B1D14636-E5D4-4D27-BADE-52959907C2DCQ33260497-DBD11F57-9732-488A-9009-5BE0FB6F0AC1Q33273063-31497229-99FD-4757-93D0-5F851FB59DE0Q33292779-3C79047E-B96B-4ED8-AA94-A606BCFF605DQ33346321-38236CC7-7066-4FF1-8AFC-14A6189C21D7
P2860
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Efficacy of a bivalent L1 viru ...... a randomised controlled trial.
@en
Efficacy of a bivalent L1 viru ...... a randomised controlled trial.
@nl
type
label
Efficacy of a bivalent L1 viru ...... a randomised controlled trial.
@en
Efficacy of a bivalent L1 viru ...... a randomised controlled trial.
@nl
prefLabel
Efficacy of a bivalent L1 viru ...... a randomised controlled trial.
@en
Efficacy of a bivalent L1 viru ...... a randomised controlled trial.
@nl
P2093
P50
P1433
P1476
Efficacy of a bivalent L1 viru ...... a randomised controlled trial.
@en
P2093
Abner P Korn
Anne Schuind
Cecilia M Roteli-Martins
Daron G Ferris
David Jenkins
Diane M Harper
Gary Dubin
GlaxoSmithKline HPV Vaccine Study Group
Julio Teixeira
Mark M Blatter
P304
P356
10.1016/S0140-6736(04)17398-4
P407
P577
2004-11-01T00:00:00Z